🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

So proud of my colleague Anil Tibdewal who’s presenting on #PrecisionManagement of #Oligometastatic disease in #LungCancer at the #LMIC plenary session on the final day of #WCLC23 IASLC Tata Memorial Hospital TMC Radiation Oncology Naveen Mummudi 👏👏👏

Defining oligometastatic disease (OM) is tricky: is it by the number of sites or its biology? Both perspectives probably hold the answer. The timing and method of local ablative therapy differ across studies. In low to middle income regions, the challenges of treating OM

Honored and privileged to deliver a Plenary Talk on Precision Management of Oligometastatic NSCLC at #WCLC23 #IASLC Rima Pathak MD Amiya Agrawal MD TMC Radiation Oncology Tata Memorial Hospital Devayani Niyogi Sabita Jiwnani Andrea Bezjak RadOncResearch Dr (Prof). Vijay Patil

Top 9 posts you dont wanna wiss from WCLC Dr. Estela Rodriguez Chul Kim Hidehito HORINOUCHI Rami Manochakian MD, FASCO Cancer Education Christine Lovly, MD, PhD, FASCO AnnabelleGurwitch Prunella Blinman Narjust Florez, MD, FASCO #Cancer #Oncologists #CancerSurvivor #Twitter #Oncology #Oncodaily oncodaily.com/9762.html

Proud of you Amiya Agrawal MD More to come

Thank you for the kind words Radiation Oncology. I have learned a lot from my mentors at PMH, Toronto and TMH, Mumbai Princess Margaret Cancer Centre Andrea Bezjak Meredith Giuliani Rima Pathak MD TMC Radiation Oncology Tata Memorial Hospital radonc.utoronto.ca/news/utdro-pre…

The Program Committee invites you to participate in the #WCLC24 by submitting your scientific abstract(s). Deadline is April 5, 2024 @ midnight. Guidelines, abstract types accepted, important dates, FAQs & more information available here: wclc2024.iaslc.org/call-for-abstr… #LCSM #IASLC50

Don’t miss the opportunity to attend and present at IASLC #WCLC24 SanDiegoCounty Dr. Nina Niu Sanford Jeff Ryckman Shankar Siva Ben Slotman Alex Louie MD, PhD Simon Lo Drew Moghanaki

Congratulations Rima Pathak MD

Ongoing Radiation oncology Workshop at #WCLC24 covering important aspects of Rad Onco for Lung Cancer, #Reirradiation #SBRTBoost #SBRT for Oligoprogression Kristin Higgins RadOncResearch Dr. Fabio Moraes Pranshu Mohindra IASLC @

Lear More about Challenges & Controversies in Immunotherapy from Clarissa Baldotto, Misako Nagasaka, Anil Tibdewal, @ArielleElkrief, David Gandara & ProfSiowMingLee, who are currently presenting at #WCLC24. #LCSM #IASLC50 #LungCancer

Interesting session on Challenges and Controversies of Immunotherapy #WCLC24 #IASLC #BrainMetastases #Microbiome Dr Akhil Kapoor @ArielleElkrief Clarissa Baldotto, Misako Nagasaka, @ArielleElkrief, David Gandara & ProfSiowMingLee

Learn More about Novel Immunotherapy Strategies & Combinations during #WCLC24 from current speakers Anil Tibdewal, Melina Marmarelis, Charu Aggarwal, MD, MPH, FASCO and others! #LCSM #IASLC50 #LungCancer

Explore our Regional series on Immunotherapy in #lungcancer tailored to LATAM, SE Asia, & Eastern Europe! Don’t miss the chance to learn from global experts! Register at bit.ly/RWS24 IASLC Thoracic Oncology Group of Australasia Narjust Florez, MD, FASCO Anil Tibdewal Stephen V Liu, MD

📢 🚨#lungcancer peeps. Please consider Prof Andrea Bezjak from University of Toronto for your next IASLC president! A very deserving candidate and a great representative for #radonc!!! Laura Dawson #lcsm

🚨CM-577, long term🚨 Resected E/GEJ cancer s/p neoadjuvant CRT + surgery; path residual disease: 🔍Randomized: 12 m nivolumab vs. Surveillance Nivo demonstrated: ✅⬆️DFS ✅⬆️DMFS ✅⬆️OS 🔥PDL1>1 and Esophagus location > benefit 🧐Don’t be fooled be p=0.1 for OS. Study

Dr Reena Engineer from TMC Radiation Oncology presents results from Ph3 randomised POLCA-GB trial for LA Gall Bladder Ca #ASCO25 Addition of NACRT to NACT shows ✅Better response to Neoadjuvant Rx ✅Higher R0 resection rates ✅Higher EFS (4.9 Vs 10.6 mos) ✅Higher OS (10.1 Vs 21.8 mos)

Honored to share highlights of Reena Engineer’s presentation of POLCAGB phase III trial at #ASCO2025, a game changer for locally advanced gallbladder cancer Neoadj CRT vs CT alone: 🌟 Nearly doubled mOS (21.8 vs 10.1 months) 🌟 Significantly improved R0 resection (51.6% vs 29.7%)